Open an account

Telomir Pharmaceuticals

TELO · NASDAQ

$1.01−$0.03 (−2.88%)TodayMarket closed ·
Prev close $1.04

About TELO

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The company is headquartered in Miami, Florida. The company went IPO on 2024-02-09. The firm's lead candidate, Telomir-1 (Telomir-Zn), is an investigational therapy that has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, epigenetic regulation, mitochondrial function, and genomic stability. Telomir-1 is an oral small molecule metal ion regulator designed to extend telomere caps, maintain cellular balance, and combat oxidative stress, a key driver of aging and disease progression. By modulating essential metal ions such as iron, and copper, Telomir-1 may help protect against age related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease, and Age-related Macular Degeneration (AMD), as well as Type 2 diabetes, breast cancer, and Alzheimer’s disease.

Employees
5
Headquarters
Miami, Florida
Listed
Feb 9, 2024
Sector
Health Care
Industry
Pharmaceuticals
Website
telomirpharma.com

TELO key statistics

Market cap
74.35M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
126.51K
Volume
78.96K
Open price
$1.02
High today
$1.05
Low today
$1.00
52 Week high
$1.70
52 Week low
$0.8885

Telomir Pharmaceuticals (TELO) at a glance

As of Oct 20, 2026, Telomir Pharmaceuticals (TELO) shares are priced at $1.01, giving the company a market cap of 74.35M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.00 and $1.05. The current price is 1.0% above the day's low and 3.8% below its high.

Volume so far is 78.96K shares, below the average of 126.51K shares a day.

Over the past year Telomir Pharmaceuticals has ranged from $0.8885 to $1.70, and now sits 15% of the way up that range.

Telomir Pharmaceuticals met or beat analyst EPS estimates in 2 of the last 5 quarters. In Q4 FY25 it reported -$0.28 per share against an estimate of -$0.0714.

The average analyst price target is $4.08, 304.0% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $4.08
Low
$4.04
Now
$1.01
High
$4.20

TELO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 5 quarters, by 44.7% on average.

  1. Q4 FY24: reported -$0.098 per share against an estimate of -$0.051
  2. Q1 FY25: reported -$0.07 per share against an estimate of -$0.102
  3. Q2 FY25: reported -$0.17 per share against an estimate of -$0.0816
  4. Q3 FY25: reported -$0.03 per share against an estimate of -$0.0714
  5. Q4 FY25: reported -$0.28 per share against an estimate of -$0.0714

TELO news

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releaseACCESS Newswire

    Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer

  • Press releaseACCESS Newswire

    Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models

  • Press releaseACCESS Newswire

    Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging

  • Aniket Verma

    Coinbase CEO Brian Armstrong Says His Biotech Company Is Working On 'Extending' Human Lifespan: Here Is How They Plan To Do It

  • Press releaseACCESS Newswire

    Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models

  • Press releaseACCESS Newswire

    Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development

  • Press releaseACCESS Newswire

    Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells

Similar companies

Companies in the same industry as Telomir Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.